Shield Therapeutics positioned for profitability with Viatris deal and its additional capital (VIDEO)

Shield Therapeutics (LON:STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.

Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here.

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR.

Find more news, interviews, share price & company profile here for:

    You can also listen to our interviews on: 

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp
    Shield Therapeutics positioned for profitability with Viatris deal and its additional capital (VIDEO)

    Other Interviews

    More News

    Ask your questions

    Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

    I have questions